# US 2026/0216060 A1 · Compositions for glucose-responsive drug delivery systems via multifunctional hydrogel-based microneedle

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216060 A1
- Document ID: US20260216060A1
- Status: Published application
- Kind: A1
- Application number: 19/120,328
- Filed: 2023-10-16
- Published: 2026-07-30
- Earliest claimed: 2022-10-14
- Assignees: The Governing Council of the University of Toronto
- Applicants: The Governing Council of the University of Toronto
- Inventors: XIAOYU WU; AMIN GHAVAMI NEJAD; FULE LIU; BRIAN LU; ADRIA GIACCA; SAKO MIRZAIE; MELISA SAMARIKHALAJ
- Web page: https://patentgrep.com/patent/US20260216060A1

## CPC

- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61B 5/14514: {using means for aiding extraction of interstitial fluid, e.g. microneedles or suction}
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/4839: {combined with drug delivery}
- A61K 38/26: Glucagons
- A61K 38/28: Insulins
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61B 2562/12: Manufacturing methods specially adapted for producing sensors for in-vivo measurements
- A61M 2037/0023: {Drug applicators using microneedles}
- A61M 2037/0053: {Methods for producing microneedles}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with needle height dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa~7.5) that quickly and spontaneously crosslinks upon mixing of the polymer solutions by auto-oxidation of catechol groups and reversible interactions between AFBA and catechol functional groups in the absence of any chemical crosslinking agent. The DA and AFBA content were selected for conjugation into the backbone of the HA polymer for the desired hormone delivery profile. The patch provides high drug loading capacity for long-term drug delivery application. The crosslinking mechanism for microneedle fabrication is biocompatible and beneficial for sustaining hormone drug stability and bioactivity as it does not require harsh crosslinking conditions. Facile pH adjustment of the matrix hydrogel can be easily casted into a microneedle patch without multistep processes that conventional patch polymerization requires. The present matrix microneedle patch demonstrates sufficient skin penetration, rapid swelling in interstitial media, high drug loading capacity and effective hypo/hyperglycemia prevention by the automated hypo/hyperglycemia-triggered delivery of hormones through the skin.

## Claims

### Claim 1

(canceled)

### Claim 2

A matrix microneedle patch device for monitoring and/or treating high blood sugar or preventing low blood sugar, comprising:
a base;
an array of microneedles extending from, and away, from said base, each microneedle of said array and said base being made of a crosslinked mixture of a first fraction of natural and/or synthetic polymeric backbones having catechol containing molecules conjugated thereto and a second fraction of natural and/or synthetic polymeric backbones and glucose-sensing molecules containing glucose-responsive moieties conjugated thereto, the first and second fractions being crosslinked via catechol-catechol crosslinkages and catechol-glucose-sensing molecules crosslinkages in an absence of chemical crosslinking agents; and
blood glucose-reducing agents entrapped within the crosslinked polymeric backbones or blood glucose-raising agents non covalently bonded to catechol moieties in the catechol containing molecules.

### Claim 3

A matrix microneedle patch device having contained therein a composition for treating high blood sugar or preventing low blood sugar, comprising:
a microneedle patch with a base;
an array of microneedles extending from and away from said base;
blood glucose-raising agents or blood glucose-reducing agents loaded into the patch;
each microneedle of said array and said base being made of a mixture of natural and/or synthetic polymeric backbones;
catechol containing molecules covalently conjugated to the natural and/or synthetic polymeric backbones, wherein, the catechol is either covalently or non-covalently coupled to one another that form crosslinkages between the polymeric backbones;
glucose-sensing molecules containing glucose-responsive moieties covalently conjugated to the natural and/or synthetic polymeric backbones that interact with catechol containing molecules, wherein the glucose-responsive moieties reversibly interact or dissociate with the catechol containing molecules in response of the concentration of a diol-containing compound; and
wherein when blood glucose-reducing agents are present they are entrapped and prevents blood glucose-raising beyond a preselected blood glucose level, and when the blood glucose-reducing agents are present they are non-covalently bonded to catechol moieties in the catechol containing molecules.

### Claim 4 (depends on 2)

The matrix microneedle patch device according to claim 2, wherein the natural polymeric backbones are selected from the group consisting of hyaluronan, cellulose, chitosan, chitin, alginate, collagen, gelatin, xanthan, and a combination thereof.

### Claim 5 (depends on 2)

The matrix microneedle patch device according to claim 2, wherein the synthetic polymeric backbones are selected from the group consisting of polyolefins, polyvinyls, polyesters, polyanhydrides, polyacrylates, polyurethanes, polyamides, poly(3,4-ethylenedioxythiophene) polystyrene sulfonate, polyacetylene, polypyrrole, polyindole, polyaniline or combinations or copolymers thereof.

### Claim 6 (depends on 2)

The matrix microneedle patch device according to claim 2, wherein the glucose-sensing molecules are any one or combination of lectin, synthetic phenylboronic acid (PBA) and boronic acid containing compounds bearing polymerizable groups.

### Claim 7 (depends on 2)

The matrix microneedle patch device according to claim 2, wherein the glucose-reducing agent is selected from the group consisting of peptide hormones that reduce blood glucose levels.

### Claim 8 (depends on 7)

The device according to claim 7, wherein the peptide hormones that reduce blood glucose levels include any one or combination of insulin, GLP-1, GLP-1 analogues, pramlintide, gama-aminobutyric acid, glucose-dependent insulinotropic polypeptide and GLP.

### Claim 9 (depends on 2)

The matrix microneedle patch device according to claim 2, wherein the glucose-responsive moieties exhibit higher interaction with glucose in response to high glucose level causing swelling of the microneedle and rapid release of the blood glucose-reducing agent.

### Claim 10 (depends on 2)

The matrix microneedle patch device according to claim 2, wherein the glucose-raising agents are selected from the group consisting of peptide hormones that increases blood glucose levels.

### Claim 11 (depends on 10)

The device according to claim 10, wherein the peptide hormones that increases the blood glucose levels include any one or combination of glucagon, glucagon analogues, epinephrine, and epinephrine analogues, norepinephrine and norepinephrine analogues.

### Claim 12 (depends on 2)

The matrix microneedle patch device according to claim 2, wherein the glucose-responsive moieties exhibit lower interaction with glucose in response to low blood glucose levels causing the interaction of the glucose-responsive moieties with catechol components and rapid release of the blood glucose-raising agent.

### Claim 13 (depends on 2)

A kit, comprising:
at least two matrix microneedle patch devices according to claim 2 with one of said patch devices containing the glucose-reducing agents and the other containing the blood glucose-raising agents, and instructions for a user to affix the patch devices to their body.

### Claim 14

A method of producing a matrix microneedle patch containing blood glucose-reducing agents or blood glucose-raising agents, comprising:
providing a mold of preselected size for receiving polymer solutions therein, which once the patch is produced it has a base section and microneedles extending away from said base section;
mixing a first polymer solution of natural and/or synthetic polymeric backbones having catechol containing molecules covalently conjugated to the polymeric backbones with blood glucose-reducing agents or blood glucose-raising agents and a second polymer solution of natural and/or synthetic polymeric backbones containing glucose-responsive moieties covalently conjugated to the polymeric backbones that interact with the catechol containing molecules such that the natural and/or synthetic polymeric backbones crosslink by auto-oxidation of catechol groups and reversible interactions between the glucose-sensing molecule and the catechol functional groups in the absence of any chemical crosslinking agent; and
wherein when blood glucose-reducing agents are present they are entrapped and prevent the blood glucose level rising beyond a preselected blood glucose level, and when the blood glucose-increasing agents are present they are non-covalently bonded to catechol moieties in the catechol containing molecules and increase blood glucose levels and prevents reduction of blood glucose beyond a preselected blood glucose level.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the natural and/or synthetic polymeric backbones are crosslinked upon mixing of the polymer solutions at a specific weight ratio, wherein a weight ratio of the catechol-conjugated natural and/or synthetic polymers to glucose-sensing molecules conjugated natural and/or synthetic polymeric backbones are about 0.25:3 to about 3:0.25.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the weight ratio is about 1.1 to about 3:1.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the weight ratio is about 2:1.

### Claim 18 (depends on 3)

The matrix microneedle patch device according to claim 3, wherein the natural polymeric backbones are selected from the group consisting of hyaluronan, cellulose, chitosan, chitin, alginate, collagen, gelatin, xanthan, and a combination thereof and the synthetic polymeric backbones are selected from the group consisting of polyolefins, polyvinyls, polyesters, polyanhydrides, polyacrylates, polyurethanes, polyamides, poly(3,4-ethylenedioxythiophene) polystyrene sulfonate, polyacetylene, polypyrrole, polyindole, polyaniline or combinations or copolymers thereof.

### Claim 19 (depends on 3)

The matrix microneedle patch device according to claim 3, wherein the glucose-sensing molecules are any one or combination of lectin, synthetic phenylboronic acid (PBA) and boronic acid containing compounds bearing polymerizable groups and the glucose-reducing agent is selected from the group consisting of peptide hormones that reduce blood glucose levels.

### Claim 20 (depends on 3)

The matrix microneedle patch device according to claim 3, wherein the glucose-sensing molecules are any one or combination of lectin, synthetic phenylboronic acid (PBA) and boronic acid containing compounds bearing polymerizable groups, the glucose-reducing agent is selected from the group consisting of peptide hormones that reduce blood glucose levels and the glucose-raising agents are selected from the group consisting of peptide hormones that increases blood glucose levels.

### Claim 21 (depends on 3)

The matrix microneedle patch device according to claim 3, wherein the glucose-responsive moieties exhibit higher interaction with glucose in response to high glucose level causing swelling of the microneedle and rapid release of the blood glucose-reducing agent or the glucose-responsive moieties exhibit lower interaction with glucose in response to low blood glucose levels causing the interaction of the glucose-responsive moieties with catechol components and rapid release of the blood glucose-raising agent.
